Sam – Page 233 – biolegacy

Senate Committee Explores Value-Based Drug Pricing to Help Stem Increases

Post author:Sam
Post published:December 12, 2017
Post category:Drug Industry Daily

The Senate’s health committee held its final hearing in a set of three this year on the rising costs of prescription drugs — this time exploring how value-based pricing could…

4 Possible Biotech Takeover Targets for 2018

Post author:Sam
Post published:December 11, 2017
Post category:BioPharma

This year wasn't big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016. Source: BioSpace

Bay Area's Aduro Biotech Throws in the Towel on CRS-207, Will Wind Down Trials

Post author:Sam
Post published:December 11, 2017
Post category:BioPharma

The company is shuttering the program and focusing on other compounds in its pipeline after CRS-207 failed in studies. Source: BioSpace

GlaxoSmithKline's Nucala Wins FDA Approval for EGPA

Post author:Sam
Post published:December 11, 2017
Post category:BioPharma

The approval for EGPA is based on results from the pivotal, 52-week, Phase III MIRRA1 study, conducted as a collaboration between GSK and the NIAID, part of the US NIH.…

Tax Reform: A War on Life Sciences Innovation

Post author:Sam
Post published:December 11, 2017
Post category:BioPharma

One of the biggest concerns has been the loss of the R&D tax credit, which incentivizes companies, including life science firms, to support research. Source: BioSpace

71% of ALL Patients Achieved Complete Tumor Remission on Gilead, Kite's CAR-T Therapy

Post author:Sam
Post published:December 11, 2017
Post category:BioPharma

The ZUMA-3 study results were presented in an oral session at the Annual Meeting of the ASH in Atlanta. Source: BioSpace

Allergan Swoops in and Bags Troubled Repros Therapeutics

Post author:Sam
Post published:December 11, 2017
Post category:BioPharma

The deal is expected to close in the first quarter of 2018. Source: BioSpace

Achaogen COO Promoted to Top Post, Effective Jan. 1, 2018

Post author:Sam
Post published:December 11, 2017
Post category:BioPharma

Dr. Hillan will remain on, and Mr. Wise will join, the Company’s Board of Directors. Source: BioSpace

Sanofi Investors Crave for a Large Acquisition, Drug News

Post author:Sam
Post published:December 11, 2017
Post category:BioPharma

As Sanofi grapples with the fallout from its Dengue vaccine, the termination of its late-stage C. diff vaccine and falling short of its third quarter expectations, company investors are getting…

FDA Approves Sanofi's Admelog, the First Follow-On Insulin to Control Sugar at Mealtime

Post author:Sam
Post published:December 11, 2017
Post category:BioPharma

Admelog is a rapid-acting insulin similar to Humalog, another insulin lispro 100 Units/mL, currently approved in the U.S. Source: BioSpace